Phase III LEAP-012 Study Shows Promising Results for Intermediate-Stage HCC Treatment
The LEAP-012 phase III trial demonstrates that combining lenvatinib, pembrolizumab, and TACE significantly improves progression-free survival in patients with intermediate-stage hepatocellular carcinoma, compared to placebo plus TACE.
© Copyright 2025. All Rights Reserved by MedPath